In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus

Sun, Chun‐Guang; Falagas, Matthew E.; Wang, Rui; Karageorgopoulos, Drosos E.; Yu, Xinguang; Liu, You-ning; Cai, Yun; Liang, Beibei; Song, Xingguo; Liu, Zheyuan

doi:10.1038/ja.2011.52

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, synergy was observed with ceftriaxone in a time-kill study (44). (90), and minocycline (87%) (163). Lower synergy was reported with rifampin (50%) (164).…”

Section: Newer Studiesmentioning

confidence: 92%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

“…However, synergy was observed with ceftriaxone in a time-kill study (44). (90), and minocycline (87%) (163). Lower synergy was reported with rifampin (50%) (164).…”

Section: Newer Studiesmentioning

confidence: 92%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Otherwise, FOS + DOX combination was tested once against 24 isolates of vancomycin-resistant E. faecium, demonstrating to have synergistic or additive effect in most of cases [68]. Finally, when FOS + MIN was tested against MRSA (152, strains, 3 studies) proved to have synergistic effect in numerous cases [18,69,70]. No study reported any case of antagonism.…”

Section: Tetracyclinesmentioning

confidence: 99%

Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

et al. 2020

View full text Add to dashboard Cite

Fosfomycin is being increasingly prescribed for multidrug-resistant bacterial infections. In patients with systemic involvement, intravenous fosfomycin is usually administered as a partner drug, as part of an antibiotic regimen. Hence, the knowledge of fosfomycin pharmacodynamic interactions (synergistic, additive, indifferent and antagonistic effect) is fundamental for a proper clinical management of severe bacterial infections. We performed a systematic review to point out fosfomycin’s synergistic properties, when administered with other antibiotics, in order to help clinicians to maximize drug efficacy optimizing its use in clinical practice. Interactions were more frequently additive or indifferent (65.4%). Synergism accounted for 33.7% of total interactions, while antagonism occurred sporadically (0.9%). Clinically significant synergistic interactions were mostly distributed in combination with penicillins (51%), carbapenems (43%), chloramphenicol (39%) and cephalosporins (33%) in Enterobactaerales; with linezolid (74%), tetracyclines (72%) and daptomycin (56%) in Staphylococcus aureus; with chloramphenicol (53%), aminoglycosides (43%) and cephalosporins (36%) against Pseudomonas aeruginosa; with daptomycin (97%) in Enterococcus spp. and with sulbactam (75%) and penicillins (60%) and in Acinetobacter spp. fosfomycin-based antibiotic associations benefit from increase in the bactericidal effect and prevention of antimicrobial resistances. Taken together, the presence of synergistic interactions and the nearly total absence of antagonisms, make fosfomycin a good partner drug in clinical practice.

show abstract

“…Combination antibiotic therapy has also been proposed for the treatment of MRSA based on the in vitro synergistic activity of minocycline plus fosfomycin [57] and linezolid plus fosfomycin [58], as well as on the clinical use of vancomycin plus rifampicin [59], but more evidence is still needed to test these potential combinations.…”

Section: Treatment Of Mdr Gram-positive Vapmentioning

confidence: 99%

Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Bailey

Kalil

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

show abstract

In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus

Cited by 4 publications

References 24 publications

Fosfomycin

Fosfomycin

Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Contact Info

Product

Resources

About